Deniz Can Guven, The Editorial Board Member in BMC Cancer, shared on X:
“Out in Cancer Treatment Reviews
NOM after IO in early-stage MSI-H GI cancers.
High pCR rates (>60%)
Prompt consideration in rectal cancer
Investigational in gastric and colon cancers
An excellent review. ”
Source: Deniz Can Guven/X
